In this article, we will discuss: Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks. For more stocks, you can head to Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.
5. Pfizer Inc. (NYSE:PFE)
Number of Hedge Fund Holdings in Q4 2024: 92
Number of Hedge Fund Holdings in Q4 2025: 81
Performance Since Cramer’s Remarks: 25%
Date/Month of Cramer’s Remarks: April 10th, 2025
Pfizer Inc. (NYSE:PFE) is one of the largest pharmaceutical companies in the world. It operates in the weight loss drug market by developing a treatment that will be administered only once a month. The shares are up by 6.7% over the past year and by 25% since Cramer discussed the firm on Mad Money. One notable movement in Pfizer Inc. (NYSE:PFE)’s shares came between September 29th and October 1st, when they gained 14%. A key announcement that occurred during this time period saw the firm announce that it would lower drug prices under Medicaid to bring them in line with those in developing countries after an agreement with President Trump and be part of the Trump administration’s TrumpRx initiative. Year-to-date, Pfizer Inc. (NYSE:PFE)’s shares are up by 7.4%. However, on February 3rd, the shares closed 3.3% lower after the firm reported its fiscal fourth quarter earnings report. The results saw Pfizer Inc. (NYSE:PFE) post $17.6 billion in revenue and $0.66 in adjusted earnings per share. Here is what Cramer had said about the firm in April 2025:
“Well, let me tell you something… right now, we have a government that is trying to figure out whether it’s going to tax the heck out of drug companies, raise tariffs outta drug companies or not. I can’t make a prediction anymore. It yields 8%. Normally I say fine, but you know what? Let’s say you decide, you know what, we need big tariffs on Pfizer. You’ll say, wow, I’m buying that stock at 18 rather than 21. So I’m going to have to say, pass.”
4. GSK (NYSE:GSK)
Number of Hedge Fund Holdings in Q4 2024: 38
Number of Hedge Fund Holdings in Q4 2025: 43
Performance Since Cramer’s Remarks: 38.9%
Date/Month of Cramer’s Remarks: March 25th, 2025
Pharma giant GSK (NYSE:GSK) made a move to enter the weight loss market earlier this year after it announced that it would acquire 35Pharma and bolster its portfolio to include the HS235 drug that can be used for fat-selective weight loss and muscle mass preservation. Its shares are up by 38% over the past year and by a similar percentage since Cramer discussed the firm in March 2025. GSK (NYSE:GSK) ‘s stock closed 7.3% higher on February 4th, 2026, after the firm reported its fourth quarter earnings report. The results saw the firm post 8.6 billion pounds in revenue and 25.5 pence in earnings to beat analyst estimates. On October 29th, 2025, GSK (NYSE:GSK) ‘s shares closed 5% higher after the firm’s third-quarter earnings saw it raise its 2025 revenue growth estimates to a 6% to 7% from an earlier 3% to 5%. It posted 8.6 billion pounds in revenue and 55 pence on earnings per share to also beat estimates. Here is what Cramer said about the firm a year back:
“Not at all, not at all. I like GSK very much. I think it’s a very good company. I think Dame Walmsley’s doing a terrific job. I think the stock, the fact that it’s at a very low PE and it yields 4%, that’s my kind of stock. I think you put it away, buy it, and put it away.”
3. Novo Nordisk A/S (NYSE:NVO)
Number of Hedge Fund Holdings in Q4 2024: 64
Number of Hedge Fund Holdings in Q4 2025: 55
Performance Since Cramer’s Remarks: 44%
Date/Month of Cramer’s Remarks: April 11th, 2025
Novo Nordisk A/S (NYSE:NVO) is a key player in the weight loss drug industry. The firm made a splash earlier this year when it became the first to secure the FDA’s approval for a weight loss drug pill. With the announcement occurring on December 22nd, Novo Nordisk A/S (NYSE:NVO)’s shares closed 7.3% higher on the 23rd. Since Cramer discussed the firm in April 2025, the shares are up by 44%, while they are down by 48% over the year. 2026 hasn’t been a great year for Novo Nordisk A/S (NYSE:NVO)’s shares either, as they are down by 31% year-to-date. On February 23rd, the shares closed 16.4% lower as the firm reported that its next-generation weight loss drug, CagriSema, failed to match rival Eli Lilly’s offering. The announcement marked another day of weak performance, as Novo Nordisk A/S (NYSE:NVO)’s stock had dipped by 19% between February 2nd and February 4th after the pharma company surprised investors through its guidance and commented that revenue and operating profit could dip between 5% and 13% each in 2026. Here’s what Cramer said about the firm on Mad Money:
“I do…. It got low enough. When it hit 3.6% yield, it was low enough. Apparently, they’re doing exactly what President Trump wants. I am a buyer at this point in Novo Nordisk, though of course I do like Eli Lilly more, but this stock has come down enough.”
2. Merck & Co., Inc. (NYSE:MRK)
Number of Hedge Fund Holdings in Q4 2024: 91
Number of Hedge Fund Holdings in Q4 2025: 100
Performance Since Cramer’s Remarks: 46%
Date/Month of Cramer’s Remarks: April 9th, 2025
Merck & Co., Inc. (NYSE:MRK) aims to make an entry into the weight loss drug market through the HS-10535 drug, which it licensed from Hanosh Pharmaceutical through a $2 billion agreement. The shares are up by 33% over the past year and by 46% since Cramer discussed the firm on April 9th. Merck & Co., Inc. (NYSE:MRK)’s shares closed 3.8% higher on November 18th after data for its heart drug Winrevair. 2026 has been a good month for the stock as it is up by 12.4% year-to-date. Between February 2nd and February 6th, the shares gained 7.6%. On February 3rd, Merck & Co., Inc. (NYSE:MRK) reported its fiscal fourth quarter earnings report. The results saw the firm post $16.4 billion in revenue and $2.04 in adjusted profit per share to beat analyst estimates of $16.2 billion and $2.01. Additionally, Merck & Co., Inc. (NYSE:MRK) also revealed that it had expected to earn $65.5 billion to $67 billion in revenue, which sat below analyst estimates. The firm remarked that the loss of exclusivity for several medicines would impact its revenue more than what analysts were expecting. Cramer advised viewers to hold on to their Merck & Co., Inc. (NYSE:MRK) shares on Mad Money:
“You know, first of all, you’re not alone. St. Merck, as we used to call it, has turned into just a complete nightmare. I think that if you buy Merck at a 4% yield though, you’re gonna do well. It did touch $76 today. It’s back to $81. I feel for what you’re doing… It is remarkable how poorly this stock acts. I do want you to stay the course with it right at this point. And I’m sorry because it is been a real tough one.”
1. Jabil Inc. (NYSE:JBL)
Number of Hedge Fund Holdings in Q1 2025: 55
Number of Hedge Fund Holdings in Q4 2025: 64
Performance Since Cramer’s Remarks: 47%
Date/Month of Cramer’s Remarks: June 25th, 2025
Jabil Inc. (NYSE:JBL) is one of the largest and most diversified contract manufacturing firms in the world. It is a key player in the weight loss drug industry due to its ability to manufacture the injector pens used to deliver the medicine. Jabil Inc. (NYSE:JBL)’s shares are up by a whopping 91% over the past year and by 47% since Cramer discussed the firm in June. The stock closed 6.7% lower on September 25th after the firm posted its fiscal fourth quarter earnings report. During the quarter, Jabil Inc. (NYSE:JBL)’s healthcare revenue grew by 4%, and weaknesses in other businesses meant that the growth in the firm’s AI business was insufficient to generate tailwinds for the stock. The weak performance came even though Jabil Inc. (NYSE:JBL)’s fourth quarter revenue of $8.3 billion beat analyst estimates. Year to date, the stock is up by 8.6%. Year to date, the stock is up by 8.6%. In March, the firm’s second-quarter earnings saw it post $8.3 billion in revenue and $2.69 in core earnings per share to surpass analyst estimates. Cramer was quite optimistic about Jabil Inc. (NYSE:JBL) in a June appearance on Mad Money:
“Jabil is so terrific that even though it’s up on a spike… I am again going to bless it. Why? Because it only sells at 22 times earnings, and it’s the kind of company you need to deal with right now. They’ll understand all the tariff problems and they’ll help you.”
While we acknowledge the potential of JBL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JBL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
